Inventor · disambiguated record
Shaun M. Stewart
Also filed as: STEWART SHAUN M
3 granted patents·9 pending applications·1 citations·filing 2020–2024
51Inventor score
Top patents by PatentIndex Score
12 records- 0187US11993654B2PD-1 binding domainsMERUS NV·Filed 2022·Granted May 28, 2024·1 cites·20 claims
- 0276US2024425594A1Novel pd-1 binding domainsMERUS NV·Filed 2024·Application pending·0 cites
- 0376US2024425595A1Novel pd-1 binding domainsMERUS NV·Filed 2024·Application pending·0 cites
- 0475US2025059293A1Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapyINCYTE CORP·Filed 2024·Application pending·0 cites
- 0573US2024352143A1Anti-cd73 antibodies and uses thereofINCYTE CORP·Filed 2024·Application pending·0 cites
- 0665US12018089B2Anti-CD73 antibodies and uses thereofINCYTE CORP·Filed 2020·Granted Jun 25, 2024·0 cites·27 claims
- 0762US12060433B2CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapyINCYTE CORP·Filed 2020·Granted Aug 13, 2024·0 cites·39 claims
- 0861US2021205311A1Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 InhibitorsINCYTE CORP·Filed 2020·Application pending·0 cites
- 0959US2023159645A1Multispecific binding moieties comprising pd-1 and tgf-brii binding domainsMERUS NV·Filed 2022·Application pending·0 cites
- 1058US2022233529A1Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodiesINCYTE CORP·Filed 2021·Application pending·0 cites
- 1158US2023272055A1Anti-mutant calreticulin (calr) antibodies and uses thereofINCYTE CORP·Filed 2022·Application pending·0 cites
- 1256US2022363761A1Multispecific binding moieties comprising novel pd-1 binding domainsMERUS NV·Filed 2022·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →